FY2022 EPS Estimates for Bristol-Myers Squibb Decreased by William Blair (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMYGet Rating) – Equities researchers at William Blair reduced their FY2022 earnings per share estimates for Bristol-Myers Squibb in a research note issued on Monday, May 2nd. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings of $7.57 per share for the year, down from their prior forecast of $7.71. William Blair also issued estimates for Bristol-Myers Squibb’s Q4 2022 earnings at $1.71 EPS, Q1 2023 earnings at $2.05 EPS, Q2 2023 earnings at $2.00 EPS, Q3 2023 earnings at $2.09 EPS, FY2023 earnings at $8.03 EPS, FY2024 earnings at $8.18 EPS, FY2025 earnings at $8.31 EPS and FY2026 earnings at $8.16 EPS.

A number of other research analysts also recently commented on BMY. BMO Capital Markets raised their target price on shares of Bristol-Myers Squibb from $87.00 to $92.00 in a research report on Monday. Barclays lifted their price objective on shares of Bristol-Myers Squibb from $66.00 to $68.00 in a research report on Monday. StockNews.com began coverage on shares of Bristol-Myers Squibb in a research report on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Truist Financial lifted their price objective on shares of Bristol-Myers Squibb from $76.00 to $81.00 in a research report on Monday. Finally, Wells Fargo & Company lifted their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $71.33.

NYSE BMY opened at $76.31 on Thursday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.43 and a current ratio of 1.32. The company has a market capitalization of $162.47 billion, a price-to-earnings ratio of 27.06, a price-to-earnings-growth ratio of 1.59 and a beta of 0.49. The company’s 50-day simple moving average is $73.12 and its two-hundred day simple moving average is $65.46. Bristol-Myers Squibb has a one year low of $53.22 and a one year high of $78.17.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last posted its earnings results on Friday, April 29th. The biopharmaceutical company reported $1.96 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.05. The business had revenue of $11.65 billion for the quarter, compared to the consensus estimate of $11.34 billion. Bristol-Myers Squibb had a net margin of 13.31% and a return on equity of 48.37%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.74 EPS.

The business also recently announced a quarterly dividend, which was paid on Monday, May 2nd. Shareholders of record on Friday, April 1st were given a dividend of $0.54 per share. This represents a $2.16 annualized dividend and a yield of 2.83%. The ex-dividend date of this dividend was Thursday, March 31st. Bristol-Myers Squibb’s dividend payout ratio is presently 76.60%.

In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 25,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, March 21st. The shares were sold at an average price of $71.52, for a total transaction of $1,788,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Christopher S. Boerner sold 29,532 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, March 14th. The shares were sold at an average price of $69.20, for a total transaction of $2,043,614.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 165,668 shares of company stock worth $11,459,888. 0.09% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in BMY. Mizuho Securities Co. Ltd. lifted its stake in shares of Bristol-Myers Squibb by 239.0% in the 1st quarter. Mizuho Securities Co. Ltd. now owns 339 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 239 shares during the period. Nauset Wealth Management. LLC acquired a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at $27,000. Conrad Siegel Investment Advisors Inc. acquired a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at $28,000. Bell Investment Advisors Inc acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter valued at $29,000. Finally, Steward Financial Group LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 73.07% of the company’s stock.

Bristol-Myers Squibb Company Profile (Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Further Reading

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.